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Phosphorylation of the neuronal microtubule-associated Tau protein plays a critical role
in the aggregation process leading to the formation of insoluble intraneuronal fibrils within
Alzheimer’s disease (AD) brains. In recent years, other posttranslational modifications
(PTMs) have been highlighted in the regulation of Tau (dys)functions. Among these
PTMs, the O-β-linked N-acetylglucosaminylation (O-GlcNAcylation) modulates Tau
phosphorylation and aggregation. We here focus on the role of the PHF-1 phospho-
epitope of Tau C-terminal domain that is hyperphosphorylated in AD (at pS396/pS404)
and encompasses S400 as the major O-GlcNAc site of Tau while two additional
O-GlcNAc sites were found in the extreme C-terminus at S412 and S413. Using
high resolution NMR spectroscopy, we showed that the O-GlcNAc glycosylation
reduces phosphorylation of PHF-1 epitope by GSK3β alone or after priming by
CDK2/cyclin A. Furthermore, investigations of the impact of PTMs on local conformation
performed in small peptides highlight the role of S404 phosphorylation in inducing
helical propensity in the region downstream pS404 that is exacerbated by other
phosphorylations of PHF-1 epitope at S396 and S400, or O-GlcNAcylation of S400.
Finally, the role of phosphorylation and O-GlcNAcylation of PHF-1 epitope was probed
in in-vitro fibrillization assays in which O-GlcNAcylation slows down the rate of fibrillar
assembly while GSK3β phosphorylation stimulates aggregation counteracting the effect
of glycosylation.
Keywords: Alzheimer’s disease, microtubule-associated protein tau, phosphorylation, O-GlcNAc glycosylation,
protein aggregation, NMR spectroscopy
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INTRODUCTION
Alzheimer’s disease (AD) is defined by two types of lesions,
the extraneuronal senile plaques made of Aβ peptides and
neurofibrillary degeneration constituted by intraneuronal
inclusions of hyperphosphorylated Tau proteins. Tau is a
microtubule (MT)-associated protein which is mainly expressed
in neuronal axons under six alternatively spliced isoforms in
adult brain. Although it has been shown that its primary function
is promoting assembly and stability of MTs (Weingarten et al.,
1975; Cleveland et al., 1977), other important functions have
been described more recently at the cell membrane (Morris et al.,
2011) and in the nucleus (Sultan et al., 2011; Mansuroglu et al.,
2016) regulating cell signaling, genome expression and stability,
and neuronal plasticity at synapses. The various functions of Tau
are regulated by phosphorylation that was also shown to play a
crucial role in Tau pathogenesis related to fibrillar aggregation
in neuronal disorders referred to as tauopathies. In addition
to phosphorylation, Tau is highly regulated in its physiological
state by an intricate array of posttranslational modifications
(PTMs) including ubiquitination, acetylation, N-glycosylation,
and O-β-linked N-acetylglucosaminylation (O-GlcNAcylation)
(Hanger et al., 1998; Morris et al., 2015).
Tau is an intrinsically disordered protein and its primary
structure is divided into four regions: an N-terminal projection
domain, a proline-rich domain (PRD), a microtubule-binding
domain (MTBD), and a C-terminal region (Figure 1)
(Mandelkow et al., 1996; Buée et al., 2000). In its fibrillar
state, however, Tau MTBD forms highly ordered structures that
are disease-specific (Fitzpatrick et al., 2017; Falcon et al., 2018a,b;
Fyfe, 2018). In AD, two types of filaments, the paired helical
filaments (PHFs) and straight filaments (SFs), are the main
constituents of the neurofibrillary inclusions consisting of the
same protofilament structure, yet differing by the protofilament
assembly (Fitzpatrick et al., 2017). In these structures, the region
encompassing residues 306–378 of Tau MTBD adopt a cross-
β/β-helix fold (Figure 1). While Tau is hyperphosphorylated
in its disease-associated fibrillar state, phosphorylation sites
(as well as other PTMs) were not observed in former cryo-EM
structures of PHF-Tau from AD brains presumably due to
PTM heterogeneity failing to provide a detail view of phosphate
accommodation into filament assembly (Fitzpatrick et al., 2017).
Tau filaments in AD and cortico-basal degeneration (CBD)
were shown to be extensively modified by phosphorylation,
acetylation, trimethylation and ubiquitination with acetylation
and ubiquitination occurring mainly within the fibril cores
(Arakhamia et al., 2020). In contrast, the large majority of
Abbreviations: AD, Alzheimer’s disease; CDK2: cyclin dependent kinase 2;
Fmoc, 9-fluorenylmethoxycarbonyl; HSQC, heteronuclear single quantum
correlation; IPTG: isopropyl-β-D-1-thiogalactopyranoside; MALDI-TOF MS,
matrix-assisted laser desorption ionization-time-of-flight mass spectrometry;
NOESY: Nuclear Overhauser SpectroscopY; pS, phosphorylated Ser; gS,
O-GlcNAcylated Ser; GSK3β, glycogen synthase kinase 3β; MT, microtubule; PTM,
posttranslational modification; O-GlcNAc, O-β-linked N-acetylglucosamine;
OGT, O-GlcNAc transferase; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide
gel electrophoresis; PHF, paired helical filaments; RP-HPLC: reverse phase
high performance liquid chromatography; TFA: trifluoroacetic acid; THP:
Tris(hydroxypropyl)phosphine; TOCSY: Total Correlation SpectroscopY.
phosphorylation sites are found in the proline-rich region and
the C-terminal domain localized at the N- and C-terminal
ends of MTBD, respectively (Hanger et al., 1992, 1998, 2007).
It has been proposed that ubiquitin or poly-ubiquitin could
stabilize the stacking of β-strands along the fibril axis and
mediate inter-protofilament interfaces in straight filaments from
AD (Arakhamia et al., 2020). Therefore, diverse PTM patterns
could be crucial in mediating distinct packing of protofilaments
leading to the ultra-structure polymorphism. However, despites
increasing knowledge in site-specific characterization of Tau
PTMs and structures of Tau filaments from various tauopathies,
the mechanisms underlying fibrillization as well as the role of
abnormal phosphorylation are still not fully understood. Besides
detaching Tau from microtubules, abnormal phosphorylation
was thought to alter Tau conformation inducing accumulation of
free Tau in the cytosol into a pathological conformation prone
to self-assembly that may convert normal Tau into abnormal
oligomers that are not only the primary state of insoluble fibrils
but also acting as seeds to propagate Tau pathology from neurons
to neurons (Goedert et al., 2010, 2017).
The O-GlcNAc glycosylation is another dynamic PTM
involved in regulation of Tau, notably through impairment
of its phosphorylation and toxicity (Arnold et al., 1996; Liu
et al., 2004, 2009; Yuzwa et al., 2008). While phosphorylation is
dynamically regulated by hundreds of kinases and phosphatases,
O-GlcNAcylation is only regulated by two antagonist enzymes,
O-GlcNAc transferase (OGT) and O-GlcNAc hydrolase (OGA)
(Hart, 1997, 2014; Hart et al., 2007; Bullen et al., 2014). It
has been shown that O-GlcNAcylation of Tau does not alter
microtubule polymerization but displays intrinsic properties
to reduce in vitro fibrillization of Tau induced by heparin
without altering its conformation (Yuzwa et al., 2012, 2014).
It could rather act by increasing monomer solubility or
directly hindering interactions at play in Tau self-assembly
during the fibrillization process. Pharmacological increase of O-
GlcNAcylation upon treatment of cells or mice with inhibitors
of OGA leads to neuroprotective effects therefore constituting
a potent strategy to tackle neurodegenerative diseases and
providing a valuable alternative to kinase inhibitors (Yuzwa et al.,
2012; Graham et al., 2014).
We have recently highlighted using high resolution
NMR spectroscopy that S400 O-GlcNAcylation and S404
phosphorylation act as a unique motif regulated by a direct
PTM crosstalk inducing each other chemical shift changes
that suggest a spatial proximity between both sites in full-
length Tau protein (Bourré et al., 2018; Theillet et al., 2012).
However, the overall effect of O-GlcNAcylation in modulation
of Tau phosphorylation is at least scarce in the context
of a low phosphorylation level that mimics physiological
phosphorylation state of Tau and absent in a context of high
phosphorylation level mimicking the hyperphosphorylated state
(Bourré et al., 2018). We have previously shown in peptides,
however, that S400 O-GlcNAcylation could act as a direct
mechanism that blocks the formation of the pathological PHF-
1 phospho-epitope (pS396/pS400/pS404) in the C-terminal
domain of Tau by disrupting the sequential phosphorylation
by GSK3β (Smet-Nocca et al., 2011). Although it was shown
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FIGURE 1 | Primary structure of human Tau protein (2N4R isoform of 441 residues) indicating AT8 (pS202/pT205) and PHF-1 (pS396/pS404) phospho-epitopes
(red) and O-GlcNAc sites (green). Sites that can be either phosphorylated or O-GlcNAcylated are indicated in blue. The inset depicts a representative conformation of
AT8 phospho-epitope in its di-phosphorylated form obtained by NMR and molecular dynamics (Gandhi et al., 2015). Ultrastructure of PHF (PDB ID: 5O3L) and SF
(PDB ID: 5O3T) cores of Tau protein from AD brain (tau 306-378) are depicted by pink and cyan ribbons, respectively (Fitzpatrick et al., 2017).
that O-GlcNAcylation does not perturb the conformation
of non-phosphorylated Tau (Yuzwa et al., 2014), another
potential role relies on conformational changes occurring in
(hyper)phosphorylated Tau in which O-GlcNAcylation could
prevent abnormal conformations that promote self-assembly
into insoluble filaments.
This points to a role of the O-GlcNAc modification in the
direct crosstalk with GSK3β-mediated phosphorylation towards
regulating Tau conformation and properties in fibrillar self-
assembly. GSK3β is a constitutively active serine/threonine kinase
involved in physiological Tau phosphorylation that regulates
its binding to MT (Spittaels et al., 2000; Sun et al., 2002).
Several studies have highlighted that GSK3β preferentially
phosphorylates most of its substrates, including Tau, after
prephosphorylation (priming) by other kinases such as Protein
Kinase A, Casein Kinases 1 and 2, cdk5 or members of the
mitogen-activated protein kinase family (Singh et al., 1995; Cho
and Johnson, 2003; Li et al., 2006). In most cases, GSK3β
phosphorylates (S/T)-XXX-(pS/pT) motifs (where pS/pT is the
priming site) that is at a Ser/Thr residue located four residues
N-terminal to the priming site, more rarely at a five or six residue
N-terminal to the priming site (Leroy et al., 2010). This points
towards a regulatory role of the O-GlcNAc modification either at
the priming sites or GSK3β targeted sites. Interestingly, primed
or unprimed Tau has a differential impact on its phosphorylation
by GSK3β with functional modulation on MT binding (Cho
and Johnson, 2003; Li et al., 2006). Tau encompasses as many
as 24 strict consensus sequences for GSK3β, fourteen of these
Ser/Thr pairs were found to be phosphorylated by GSK3β
in vitro (Reynolds et al., 2002). Furthermore, it has been
shown that phosphorylation of the PHF-1 epitope does not
required priming by another kinase. Instead, priming can be
performed by GSK3β itself in which phosphorylation of the
S404 proline-directed site plays a critical role (Leroy et al.,
2010). GSK3β plays also a key role in AD pathogenesis in
which it contributes to several phosphorylation sites found in
hyperphosphorylated PHF-Tau (Hanger et al., 1992; Morishima-
Kawashima et al., 1995; Reynolds et al., 2002; Avila et al., 2010;
Hernandez et al., 2012; Llorens-Maritin et al., 2014). In AD,
it has been proposed that GSK3β could be the link between
amyloid peptide and Tau phosphorylation since activation of
GSK3β is regulated by signaling pathways targeted by amyloid
peptide (Alvarez et al., 1999; Hernández et al., 2010). On the
other hand, GSK3β regulates Aβ level and toxicity through
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Tau phosphorylation and neurodegeneration. Overexpression
of GSK3β in vivo accelerates Tau-induced neurodegeneration
while Tau-knockout mice did not exhibit deleterious effects
of GSK3β overexpression indicating that Tau mediates GSK3β
toxicity. Inhibitors of GSK3β reduce tauopathy and alleviate
neurodegeneration in vivo (Noble et al., 2005), and are therefore
considered as therapeutic agents (Engel et al., 2008; Hernandez
et al., 2009; Medina et al., 2011) highlighting the role of GSK3β
in Tau pathology.
In this study, we have investigated by NMR spectroscopy
the phosphorylation pattern induced by GSK3β with or
without priming by CDK2/cyclin A and its modulation by the
direct crosstalk with O-GlcNAcylation. A per-residue resolution
allowed a precise characterization of Tau PTMs at the protein
level prior to investigating their role in Tau fibrillization
in vitro. Furthermore, conformational changes induced by PTM
combinations of Tau PHF-1 epitope was studied in chemically
synthesized and modified peptides (Reimann et al., 2015, 2017;
Schwagerus et al., 2016) by NMR chemical shift analyses.
MATERIALS AND METHODS
Tau Mutants
TauS262A mutant was obtained by site-directed mutagenesis of
Tau2N4R (longest isoform of 441 residues) (Despres et al., 2017).
TauPHF1 mutant was obtained by gene synthesis with codon
optimization for production in E. coli. Tau proteins were cloned
into pET15b vector (Novagen) into NcoI/XhoI allowing removal
of the sequence coding for the polyhistidine tag. TauPHF1 protein
corresponds to a mutated form of Tau2N4R in which every Pro-
directed Ser/Thr phosphorylation site as well as S262, S356 and
S191 were mutated into Ala to prevent phosphorylation except
those of the PHF-1 phospho-epitope (pS396/pS404).
Production of Tau Proteins
TauS262A and TauPHF1 mutants were produced as described
previously for wild-type Tau (Qi et al., 2017). Briefly, BL21(DE3)
E. coli strains transformed with Tau mutants were grown in
M9 minimal medium enriched with 15N as nitrogen source for
15N-labeling (6g Na2HPO4, 3g KH2PO4, 0.5g NaCl, 4g glucose,
1g 15NH4Cl, 0.5g 15N-Isogro R© (Sigma), 1 mM MgSO4, 10 ml
MEM vitamin cocktails (Sigma), 100 mg ampicillin per liter)
at 37◦C until OD at 600 nm reached 0.8–0.9. For 15N/13C-
labeling, 0.5g 15N/13C-Isogro R© (Sigma) and 2g 13C6-glucose
instead of glucose were used. Then, cultures were induced
by 0.5 mM isopropyl-thiogalactoside (IPTG) and cells were
grown at 37◦C for approximately 3 hours. The bacterial pellets
harvested by centrifugation were resuspended in 40ml per
liter of culture of cation exchange equilibrium buffer (50 mM
Na2HPO4/NaH2PO4 pH 6.6, 2 mM EDTA) supplemented with
0.5% Triton X100, 2 mM DTT and cOmpleteTM EDTA-free
protease inhibitor cocktail (Roche). Cell lysis was performed
by high pressure homogenization and the soluble extract was
obtained by centrifugation at 30,000 × g for 30 min at 4◦C.
Then, heating of the soluble extract at 80◦C for 15 minutes
followed by centrifugation was performed as a first purification
step before cation-exchange chromatography (HiTrap SP 5 ml
column, GE Healthcare). Homogeneous fractions containing
full-length Tau proteins as checked by SDS-PAGE and MALDI-
TOF mass spectrometry were pooled and buffer-exchanged in
50 mM ammonium bicarbonate prior to lyophilization.
O-GlcNAcylation of Tau by OGT
ncOGT (110 kDa, nucleocytoplasmic isoform) and O-GlcNAc
Tau (hereafter named Tau-G, Table 1) was obtained as
described in Bourré et al. (2018). Briefly, 10 mg of lyophilized
Tau protein was incubated at 800 µM with ncOGT at
0.5 mg/ml and 10 mM UDP-GlcNAc in OGT reaction buffer
(50 mM KH2PO4/K2HPO4 pH 7.6, 150 mM NaCl, 1 mM
EDTA, 0.5 mM THP, 12.5 mM MgCl2) at 31◦C for 2 days.
O-GlcNAcylated Tau protein was enriched by reverse phase
high-pressure liquid chromatography (Zorbax 300SB-C8 column
5µm, Agilent). To increase amounts of Tau-G for NMR
analyses, a second round of O-GlcNAcylation/purification was
performed with the non-O-GlcNAc enriched fraction. Both
O-GlcNAc-enriched fractions were pooled together. Following
this procedure, an average of 1.8 O-GlcNAc per Tau molecule
were found by MALDI-TOF mass spectrometry considering
a mass increment of +203 Da per GlcNAc group (see
Supplementary Figures 1E–G).
Phosphorylation of Tau by CDK2/Cyclin A
CDK2 phosphorylated at T160 was produced in E. coli by
coexpression of human GST–CDK2 and S. cerevisiae GST–
Cak1 using a pGEX vector (GE Healthcare), as described
(Brown et al., 1999; Welburn and Endicott, 2005). Human
cyclin A3 (residues 174–432) lacking the destruction box was
expressed in E. coli and co-purified with phosphorylated CDK2
on glutathione sepharose resin (GE Healthcare) (Brown et al.,
1999; Welburn and Endicott, 2005). The complex was eluted
through GST digestion on column by Prescission protease in
50 mM Tris pH 7.0, 150 mM NaCl, 1 mM DTT buffer.
The complex was then buffer-exchanged in phosphorylation
buffer (50 mM Hepes, KOH pH 7.8, 12.5 mM MgCl2, 1 mM
EDTA, 5 mM DTT), concentrated at 46 µM (as determined
by Bradford assay), frozen in liquid nitrogen and stored at
−80◦C until use.
TABLE 1 | Abbreviations used for the diverse PTM combination in Tau
proteins in this study.
Protein name Posttranslational Modifications
Tau –
Tau-P CDK2/cyclin A3 phosphorylation
Tau-PP CDK2/cyclin A3 followed by GSK3β phosphorylation
Tau-P(GSK3) GSK3β phosphorylation
Tau-G OGT O-GlcNAcylation
Tau-G/P OGT O-GlcNAcylation and CDK2/cyclin A3 phosphorylation
Tau-G/PP OGT O-GlcNAcylation and CDK2/cyclin A3 followed by
GSK3β phosphorylation
Tau-G/P(GSK3) OGT O-GlcNAcylation and GSK3β phosphorylation
Tau protein refers to either TauS262A or TauPHF1 mutants.
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Tau proteins (Tau or Tau-G) were incubated at a final
concentration of 0.1 mM with the recombinant CDK2/cyclinA3
complex and 5 mM ATP in phosphorylation buffer at 22◦C
overnight. After incubation, the kinase was removed by a heating
step at 80◦C for 15 min and subsequent centrifugation. Tau
proteins were then buffer-exchanged in 50 mM ammonium
bicarbonate prior to lyophilization. Overall phosphorylation
levels were determined by MALDI-TOF mass spectrometry
analyses considering a mass increment of +80 Da per phosphate
group. Tau or Tau-G proteins phosphorylated by CDK2 were
hereafter named Tau-P or Tau-G/P, respectively (Table 1).
Phosphorylation of Tau by GSK3β
BL21(DE3) E. coli strains transformed with a pGEX vector (GE
Healthcare) carrying the human gsk3β were grown in 1L LB
at 37◦C for 3 hours until OD at 600 nm reached 0.8–0.9, then
the culture was cooled down to 20◦C and protein induction
was performed at 20◦C overnight upon addition of 0.2 mM
IPTG. Harvested cells were resuspended in 40 ml extraction
buffer (PBS, 10% glycerol, 1% Triton X-100, 10 mM EDTA,
2 mM DTT complemented with protease inhibitor cocktail)
and cell lysis was performed by high pressure homogenization.
Soluble proteins were isolated by centrifugation at 30,000× g for
30 min at 4◦C followed by purification on 1 ml of glutathione
sepharose resin (GE Healthcare) per liter of culture. Resin beads
were incubated with the soluble extract at 4◦C for 3 hours
and extensively washed with the extraction buffer, then with
phosphorylation buffer supplemented with 50% glycerol. The
GST-GSK3β fusion protein on resin beads was stored at −20◦C
until further use.
Tau proteins (Tau, Tau-G, Tau-P or Tau-G/P) were incubated
at final concentrations of 0.1 mM with the recombinant GSK3β
kinase (the beads of GST-GSK3β kinase were washed with
phosphorylation buffer for glycerol removal) and 5 mM ATP
at 30◦C overnight in phosphorylation buffer. After incubation,
resin beads were removed by centrifugation and heating of
the supernatant was performed at 80◦C for 15 min followed
by centrifugation. Tau proteins were then buffer-exchanged in
50 mM ammonium bicarbonate prior to lyophilization. Overall
phosphorylation levels were determined by MALDI-TOF mass
spectrometry analyses. Tau, Tau-G, Tau-P or Tau-G/P proteins
phosphorylated by GSK3β were hereafter named Tau-P(GSK3),
Tau-G/P(GSK3), Tau-PP or Tau-G/PP, respectively (Table 1).
Peptide Synthesis, Purification, and
Characterization
All reagents, amino acids, and solvents were purchased from
commercial suppliers and used without further purification if
not further mentioned. Solvents- acetonitrile, dimethylchloride,
dimethylformamide (DMF)- were purchased from ACROS
ORGANICS. Peptides were synthesized on SyroXP-I peptide
synthesizer (Multi-SynTech, Witten, Germany) according
to standard Fmoc/tBu chemistry using O-(benzotriazol-1-
yl)-N,N,NORGANICS. Peptides were synthesiz-phosphate
(HBTU)/ hydroxybenzotriazole (HOBt) and preloaded resins
(Novabiochem). Fmoc-Ser/Thr(PO(OBzl)OH)-OH (Bachem)
was activated with N-[(Dimethylamino)-1H-1,2,3-triazolo-
[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium
hexafluorophosphate N-oxide (HATU)/ diisopropylethylamine
(DIPEA) and coupled manually to the resin. DIPEA was added
in 3-fold excess with respect to the amino acid and HATU.
The reaction time was extended to 6 hours. The coupling of
Fmoc-Ser(β-D-GlcNAc(Ac)3)-OH was carried out with 2 eq. of
the amino acid, HBTU, HOBt and DIPEA in DMF over a time
of 6 h (Schwagerus et al., 2016; Reimann et al., 2017). A mixture
of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and piperidine
(2% each) in DMF was used for Fmoc deprotection. Peptides
were cleaved from the resin by treatment with trifluoroacetic
acid (TFA)/triisopropylsilane (TIS)/H2O (95/2.5/2.5) for 3 hours
followed by precipitation with cold diethyl ether.
Purification was carried out by preparative reversed phase
HPLC on a Knauer Smartline system (Knauer, Berlin, Germany)
equipped with a Luna C8 column (10 µm, 250 × 21.20 mm;
Phenomenex, Torrance, CA, United States) running with
acetonitrile/0.1% TFA and water/0.1% TFA gradient at
20 mL/min. Purified peptides were characterized by analytical
HPLC and high resolution MS. The analytical HPLC was
carried out with a VWR-Hitachi Elite LabChrom system (VWR,
Darmstadt, Germany) equipped with a Luna C8 column (5 µm,
250 × 4.6 mm; Phenomenex, Torrance, CA, United States).
Peptide mass to charge ratios were measured by using an
Agilent 6210 ESI-TOF (Agilent Technologies, Santa Clara, CA,
United States) (Table 1).
NMR Spectroscopy
NMR experiments were performed at 293K on a Bruker 600 MHz
SB Avance III HD and 900 MHz Avance NEO spectrometer
(Bruker, Karlsruhe, Germany) equipped with 5-mm cryogenic
triple resonance probe heads. For NMR experiments, 15N-
labeled proteins and unlabeled peptides were dissolved at
0.2 mM and 2 mM, respectively, in a buffer containing 25 mM
NaH2PO4/Na2HPO4 pH 6.6, 25 mM NaCl, 2.5 mM EDTA, 1 mM
DTT and 5% D2O either in a volume of 200 µl (in 3 mm tubes)
or in 300 µl (in Shigemi tubes). All 1H spectra were calibrated
with 1 mM sodium 3-trimethylsilyl-3,3’,2,2’-d4-propionate as a
reference. 1H spectra were acquired with 64 scans and 32 dummy
scans, and a spectral windows of 14 ppm centered on 4.7 ppm
sampled with 32k points. For 2D and 3D experiments, a spectral
window of 14 ppm centered on 4.7 ppm was used for the
proton dimension.
For peptide assignment, standard NOESY and TOCSY
experiments were recorded on peptides with 200 and 69 ms
mixing times respectively, with 4096 and 512 points and using a
DIPSI2 sequence for mixing. TOCSY and NOESY spectra were
recorded with 32 scans and 64 scans per increment (and 128
dummy scans), respectively, with spectral windows of 13.98 and
10.0 ppm in each proton dimension centered on 4.69 ppm.
1H-15N HSQC spectra were recorded at nitrogen-15 natural
abundance with 128 scans per increment, with 2048 and 128
points in the proton and nitrogen dimensions, respectively, and
with a window of 25 ppm centered on 118 ppm for the nitrogen
dimension. 1H-13C HSQC spectra were recorded with 32 scans
per increment, with 1440 and 512 points in the proton and carbon
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dimensions, respectively, and with a window of 80 ppm centered
on 45 ppm for the carbon dimension.
For 15N-labeled proteins, 1H-15N HSQC spectra were
recorded with 32 scans per increment and 32 dummy scans with
3072 and 512 points in the proton and nitrogen dimensions,
respectively, and with a window of 25 ppm centered on
118 ppm for the nitrogen dimension. Heteronuclear experiments
were recorded with a WATERGATE sequence for water
suppression and a double INEPT (INsensitive nuclei Enhanced
by Polarization Transfer) for sensitivity improvement. All
experiments were acquired with a recycle delay of 1s.
Assignment of phosphorylation sites in CDK2/GSK3β
phosphorylated TauS262A protein required the acquisition
of three-dimensional NMR experiments on 15N/13C-labeled
Tau sample at 293K. The HNCACB and HN(CO)CACB
experiments were recorded with non-uniform sampling with
32 scans per increment and 16 dummy scans, with 1540, 90
and 180 points in the proton, nitrogen and carbon dimensions,
respectively, and with a window of 25 ppm and 60 ppm
centered on 118 ppm and 44 ppm for the nitrogen and carbon
dimensions, respectively. The HN(CA)NNH experiment
was recorded with non-uniform sampling with 24 scans per
increment and 16 dummy scans, with 2048, 120 and 100 points
in the proton and both nitrogen dimensions, respectively,
and with a window of 25 ppm centered on 118 ppm for the
nitrogen dimensions.
O-GlcNAc and phosphorylation levels were determined for
individual Ser/Thr residues based on intensity of their respective
amide correlations of modified and non-modified isoforms from
the 1H-15N HSQC experiment. Resonance assignment, peak
intensity and integration are given for phosphorylation and/or
O-GlcNAcylation sites in TauPHF1 proteins (see Supplementary
Table 1). Percentage of phosphorylation for a given residue
was calculated as the peak intensities corresponding to phospho
isoforms I(p) on the sum of total peak intensities including
non-modified I(np/ng) and O-GlcNAcylated I(g) isoforms as
described in Equation (1). Percentage of O-GlcNAcylation is
calculated similarly as described in Equation (2). Note that
modification of a given residue could affect resonances of vicinal
residues leading to resonance splitting, each corresponding
to a specific isoform (as exemplified by S400 and S404).
Therefore, I(p), I(g) or I(np/ng) corresponds to the sum of
peak intensities of a given residue in its phosphorylated,
O-GlcNAcylated or non-modified state, respectively, which could










The levels of phosphorylation or O-GlcNAcylation can either
be determined using peak integration to take into account
changes of relaxation of amide 1H and 15N upon modification.
However, overlapping peak could lead to misinterpretation of
modification levels. A comparison of values obtained from
peak intensities and peak integrals gives similar results (see
Supplementary Table 2).
MALDI-TOF Mass Spectrometry
Tau proteins were analyzed by MALDI-TOF MS (Axima
Assurance, Shimadzu) in a linear positive ion mode with
sinapinic acid matrix after ZipTip R©-C4 desalting (Millipore). For
the calculation of overall phosphorylation and O-GlcNAcylation
levels, m/z increments of +80 Da and +203 Da were
used, respectively.
Aggregation of Tau Proteins
Aggregation reactions were performed into 96-well black plate
(Greiner) in a plate reader (PHERAStar, BMG Labtech) at 37◦C
without agitation. A 5 mM aqueous stock solution of ThT
(Sigma) was filtered through a 0.22µm-filter. Tau aggregation
was induced by heparin (as sodium salt from porcine intestinal
mucosa, polydisperse heparin with molecular weight range 6–
30 kDa with most chains in the 17–19 kDa range; Sigma)
and kinetics were measured for 5–7 days with 10 µM Tau
and 2.5 µM heparin (ratio 4:1) in a buffer containing 25 mM
NaH2PO4/Na2HPO4 pH 6.6, 25 mM NaCl, 2.5 mM EDTA,
0.33 mM DTT, and 50 µM ThT. Kinetics of fibril formation
were monitored by ThT fluorescence emission at 490 nm (with
excitation at 440 nm). Aggregation reactions of each Tau PTM
isoform were performed in duplicate or triplicate and kinetics
curves represented as mean ± standard deviation were fitted
with a model of single-phase association with the GraphPad
Prism software. Different batches of kinase and phosphorylated
Tau were prepared and involved in aggregation reactions with
kinetics curves similar as those depicted in Figure 5 except for the
plateaus that differ between batches. Measurements of decrease
in soluble Tau monomers upon aggregation was performed at
end-point on SDS-PAGE (4–20% polyacrylamide) by comparing
the protein amounts before and after aggregation (equivalent
of 5µg of monomeric Tau were loaded in each lane) using
the ImageJ software (Abramoff et al., 2004). Observation of
fibril morphology was performed at the end of aggregation
reactions by transmission electron microscopy (Zeiss EM 900
microscope at 80kV equipped with a Gatan Orius 1000 camera).
Two grids per sample were prepared with 10µl of aggregation
reaction that were applied on 400-mesh hexagonal formvar-
coated grids for 90 sec. The sample-loaded grids were washed
three times with ultrapure water and drained. The grids were
then negatively stained with 2% uranyl-acetate solution for 90
sec and washed twice with ultrapure water. All TEM images
were selected as representative for each experimental condition
(i.e., Tau isoform).
For aggregation reactions induced by seeding, seeds were
prepared by incubating TauS262A (in its non-modified form)
at 10 µM and heparin at 2.5 µM (ratio 4:1) for 7 days at
37◦C. After sonication, the aggregation reaction was diluted
at 1:10e in fresh monomeric Tau at 25 µM in 100 mM MES
pH 6.9, 2mM EGTA, 1mM MgCl2, 20 mM NaF, 1 mM DTT,
100 µM ThT. Control of seeds without fresh monomeric Tau
was performed in the same conditions. As a control of the
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FIGURE 2 | Phosphorylation patterns of 15N-TauPHF1 (A,C,D,E) and 15N13C-TauS262A (B,F) by GSK3β with and without priming by CDK2. (A,B) Phosphorylation
levels of the PHF-1 epitope phosphorylated by CDK2 (red bars), CDK2/GSK3β (black bars) and GSK3β without CDK2 priming (blue bars). (C,D) 1H-15N HSQC
spectra of TauPHF1 in its non-phosphorylated form (gray), phosphorylated by CDK2 (red) and by CDK2/GSK3β (black) showing the resonances of PHF-1 residues
corresponding to the phosphorylated state (C) and the non-phosphorylated state (D). (E,F) Mass spectrometry analyses of 15N-TauPHF1 (E) and
15N13C-TauS262A (F) with the same colors as NMR spectra depicted in (C,D).
absence of free heparin, TauS262A protein at 25 µM was
incubated with 0.25 µM heparin (ratio 100:1) in the same
conditions than the seeding reactions. Seeding reactions were
incubated for a total of 5 to 7 days at 37◦C. Negative-staining
TEM imaging and SDS-PAGE measurement of decrease in
soluble monomer concentration upon assembly were performed




Crosstalk in Tau Protein
GSK3β Phosphorylation of Tau With and Without
Priming by CDK2/Cyclin A
We aim to investigate how O-GlcNAcylation modulates
phosphorylation of Tau by GSK3β with or without priming
by the proline-directed kinase CDK2/cyclin A3 (referred
hereafter as CDK2). As major O-GlcNAc sites were all
found in the C-terminus of Tau (see Supplementary
Figures 1A,B) (Bourré et al., 2018), we focused the study of
PTM crosstalk between phosphorylation and O-GlcNAcylation
in a mutated form of Tau – TauPHF1– in which most of
Ser/Thr proline-directed phosphorylation sites except those
of the PHF-1 epitope were mutated into Ala residues (see
Supplementary Figure 2). Mutations in TauPHF1 allowed to
simplify the phosphorylation pattern for further functional
studies of the PHF-1 epitope’s role in Tau aggregation.
The PTM patterns of TauPHF1 were compared to those
of the TauS262A mutant protein in which S262 mutation
into alanine prevents inhibition of Tau aggregation by S262
phosphorylation (although phosphorylation of S262 is expected
here neither with CDK2 nor GSK3β activity). TauS262A
protein exhibits a more complex phosphorylation pattern
due to the presence of 17 Ser/Thr-Pro motifs targeted by
proline-directed kinases such as CDK2 (Amniai et al., 2009;
Landrieu et al., 2010).
To establish baseline conditions, we first compare GSK3β
phosphorylation with or without priming by CDK2 in non-
O-GlcNAcylated Tau mutants, using mass spectrometry and
NMR spectroscopy (Smet et al., 2004a; Lippens et al., 2006,
2016; Landrieu et al., 2010; Danis et al., 2016, 2019).
Without priming by CDK2, only few phosphorylations were
detected in the 1H-15N HSQC spectrum of TauS262A (see
Supplementary Figures 3B,D). Resonances corresponding to
the amide group of phospho-residues exhibiting downfield
1H chemical shifts as compared to their non-phosphorylated
counterparts were the same in both TauS262A and TauPHF1
mutants indicating that GSK3β-mediated phosphorylation is
restrained to residues of the PHF-1 epitope when Tau was
not primed by CDK2 (see Supplementary Figures 3A,B).
Mass spectrometry analyses of TauPHF1-P(GSK3) indicate a
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FIGURE 3 | Phosphorylation patterns of 15N-TauPHF1-G (A,C,D,E) by GSK3β without priming by CDK2 and 15N-TauS262A-G (B,F) by GSK3β with CDK2 priming.
(A,B) Phosphorylation levels of the PHF-1 epitope. (A) TauPHF1 (blue bars) and TauPHF1-G (orange bars) phosphorylated by GSK3β. (B) TauS262A-G
phosphorylated by CDK2 (pink bars) and GSK3β after CDK2 priming (purple bars). (C,D) 1H-15N HSQC spectra of TauPHF1 (blue) and TauPHF1-G (orange)
phosphorylated by GSK3β without priming by CDK2 showing the resonances of PHF-1 residues corresponding to the phosphorylated state (C) and the
non-phosphorylated state (D). Resonances related to the O-GlcNAcylated forms of S400 is indicated by “gS400”. (E,F) Mass spectrometry analyses of
15N-TauPHF1-G (E) before (green) and after GSK3β phosphorylation (orange) and 15N-TauS262A-G (F) before (green) and after CDK2 (pink) or CDK2/ GSK3β
(purple) phosphorylation.
m/z increment of +218.0 ± 52 Da as compared to the non-
phosphorylated protein corresponding to an average of 2.7 ± 0.6
phosphate per Tau molecule. The same overall phosphorylation
level was measured for TauS262A-P(GSK3) (see Supplementary
Figures 3C,D). Assignment of phospho-residue resonances
allowed both the identification of phosphorylation sites and the
quantification of phosphorylation levels in a site-specific manner
(Landrieu et al., 2010; Theillet et al., 2012; Danis et al., 2016,
2019). Single resonances were detected for each phospho-residue
(S396, S400, S404) (Figure 2C, see Supplementary Figures 3A,B)
together with similar phosphorylation levels of 72% ± 2%
for TauS262A and 65% ± 2% for TauPHF1 (Figures 2A,B).
These data indicate a homogenous pattern of phosphorylation
corresponding to the triple phosphorylated state of the PHF-1
epitope, hereafter named PHF1-3P.
In contrast, CDK2 priming prior to GSK3β phosphorylation
of TauS262A and TauPHF1 led to distinct phosphorylation
patterns (Figures 2E,F). CDK2-mediated phosphorylation of
TauS262A (annotated by TauS262A-P) occurred at several
sites in the proline-rich region at T153, T175, T181, S199,
S202, T205, T212, T231, S235 residues (see Supplementary
Figures 4A,B), upstream the MTBD, and at S396 and S404
within the C-terminal domain while only S396 and S404
were found in TauPHF1, as expected (Figures 2A–C and
Supplementary Figures 4A–C). Mass spectrometry analyses of
TauS262A-P indicate a m/z increment of +986.34 ± 64Da as
compared to the non-phosphorylated protein corresponding
to an average of 12.3 ± 0.8 phosphate per Tau molecule
(Figure 2F). Subsequent phosphorylation by GSK3β (annotated
by TauS262A-PP) is modulated by CDK2 priming. A m/z
increment of +1374.93 ± 61 Da as compared to the non-
phosphorylated protein corresponding to an average of 17.2± 0.8
phosphate per Tau molecule was found indicating an addition
by GSK3β of about 5 ± 0.8 phosphate per Tau (Figure 2F). In
TauS262A-PP, three new phosphorylation sites were identified
at S198 and S208 in the PRR resulting from priming at
S202 and T212, respectively, and S400 in the C-terminus
resulting from priming at S404 while S396 phosphorylation
level is strongly increased. Phosphorylation by GSK3β after
CDK2 priming leads to a triple phosphorylation state of
both AT8 (pS202/pT205/pS208, AT8-3P) and PHF-1 epitopes
(Figures 2B,F and Supplementary Figures 4A,B). At the PHF-
1 epitope, CDK2 phosphorylation reached 85% and 15% on
S404 and S396, respectively. After GSK3β phosphorylation, S404,
S400 and S396 were phosphorylated at a level of 95%, 80% and
88%, respectively, leading to an overall level of 80% for the
PHF1-3P epitope (75% in TauPHF1) considering a sequential
phosphorylation mechanism (Figures 2A,B, see Supplementary
Figure 4E). Together, these data indicate that PHF-1 epitope
is unique as GSK3β substrate within Tau sequence as the only
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FIGURE 4 | Neighbor-corrected structural propensity (ncSP) plots of Tau[392-411] peptide series indicating the impact of multiple PTMs on peptide conformation
(Tamiola and Mulder, 2012). Phospho and O-GlcNAc PTM sites are indicated by red and green arrows, respectively. Deviations of combined 1Hn, 15N, 1Hα, 13Cα
and 13Cβ chemical shifts of the WT (without PTM), pS404, gS400, 2P, 3P and GP peptides compared with neighbor-corrected IDP chemical shift library (Tamiola and
Mulder, 2012) illustrates conformational changes of peptide C-terminus upon pS404 which is enhanced by combination with either multiple phosphorylations or
O-GlcNAcylation.
epitope that does not require priming by another kinase. In
contrast, AT8-3P required priming at T212 by CDK2, or another
proline-directed kinase, prior to GSK3β phosphorylation.
GSK3β Phosphorylation of O-GlcNAcylated Tau With
and Without Priming by CDK2/Cyclin A
In a similar manner described for TauS262A and TauPH1, GSK3β
phosphorylation of O-GlcNAcylated forms was investigated with
and without CDK2 priming. In accordance with what we have
previously described (Bourré et al., 2018), when incubated with
full-length Tau, recombinant OGT (in its nucleocytoplasmic
isoform referred as ncOGT) provides three major O-GlcNAc sites
that are all found in the C-terminus at residues S400, S412 and
S413. These O-GlcNAcylated Tau proteins are hereafter named
Tau-G (TauS262A-G and TauPHF1-G). As the quantitative
pattern of O-GlcNAcylation is dependent on the conditions used
for the O-GlcNAc transferase reaction, we achieve a high level
of O-GlcNAc modification by reverse phase high-performance
liquid chromatography enrichment of O-GlcNAcylated species in
order to unambiguously detect perturbations of phosphorylation
patterns induced by O-GlcNAcylation. This procedure leads
to an overall O-GlcNAc level of 1.8 ± 0.3 GlcNAc per Tau
molecule and site-specific O-GlcNAcylation of 61% ± 2%,
27% ± 1% and 47% ± 2% on S400, S412 and S413,
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respectively, determined by high resolution NMR spectroscopy
on both TauS262A-G and TauPHF1-G (see Supplementary
Figures 1A,B,E,F).
GSK3β-mediated phosphorylation of TauPHF1-G drop down
to an average of 1.3 ± 0.6 phosphate per Tau molecule
(Figure 3E) with a phosphorylation level of 38% on S404 and
14% on both S400 and S396 (Figure 3A). Three resonances
were detected for the amide function of pS404 isoforms in
TauPHF1-G/P(GSK3β) representing 21%, 14% and 3% of the
total population and were assigned to pS404/gS400, pS404/pS400
and pS404/S400 isoforms (Figure 3C), respectively, based on
comparison with spectra of TauPHF1-P and TauPHF1-PP in
which resonance of pS404/S400 and pS404/pS400 were found,
respectively (Figure 2C). In contrast, O-GlcNAcylation did not
affect S404 and S396 phosphorylation by CDK2 (90% and
15%, respectively). However, subsequent GSK3β phosphorylation
is significantly reduced as compared to non-O-GlcNAcylated
Tau to ca. 36% and 40% on both S400 and S396 sites,
respectively (Figure 3B).
Hence, O-GlcNAcylation reduces GSK3β phosphorylation on
PHF-1 epitope in which S400 O-GlcNAcylation is likely involved.
Overall phosphorylation of PHF1-3P is reduced from 80 to 36%
approximately upon sequential activity of CDK2 and GSK3β,
and from 65 to 14% in the absence of CDK2 priming. In
TauPHF1-G/P(GSK3β), the overall S404 phosphorylation level
of 38% is distributed between three isoforms: 14% for PHF1-
3P, 21% for gS400/pS404 and 3% for S400/pS404, the last two
being not subjected to further phosphorylation at S400 and
S396 (Figure 3C). These data indicate that phosphorylation
and O-GlcNAcylation of respective S404 and S400 sites are
not exclusive but rather competitive. The non-phosphorylated
S404 isoform contains a higher proportion of gS400 (75%) than
the pS404 isoform (55%) indicating that O-GlcNAcylation is
preferentially associated to the non-phosphorylated isoform.
Furthermore, levels of 26% and 38% for pS400/pS404 and
gS400/pS404 isoforms, respectively, were expected considering
a S404 phosphorylation level of 65% (as PHF1-3P) and
S400 O-GlcNAcylation level of 60%. Lower values were
measured indicating that O-GlcNAcylation not only reduces
S404 phosphorylation by GSK3β (by two-fold) and directly
prevents formation of PHF1-3P epitope, but also reduces S404
phosphorylation in the S400 non-O-GlcNAc fraction indicating
a potential role of O-GlcNAcylation at S412 and S413 sites in
modulation of PHF-1 epitope phosphorylation.
In contrast, remote phospho-epitopes localized in the proline-
rich domain of TauS262A were not regulated by O-GlcNAc
modifications within the C-terminal domain. Therefore,
O-GlcNAcylation neither modulates CDK2 priming nor has a
long-range influence on phosphorylation sites localized in the
proline-rich domain.
PTMs of PHF-1 Epitope Modulate Local
Conformation of Tau Peptides
The effect of phosphorylation, O-GlcNAcylation and
combination of both PTMs on Tau conformation was
investigated by high-resolution NMR spectroscopy (see










Phosphorylation are indicated in red and O-GlcNAcylation in green.
Supplementary Figures 5A,B) in small peptides centered on
the PHF-1 epitope from amino acid 392 to 411 (according to
numbering of the longest Tau2N4R isoform of 441 residues,
hereafter named Tau[392-411], Table 2). Here, solid-phase
peptide synthesis allows the introduction of PTMs in a site-
specific manner providing homogenous modification patterns.
All peptides exhibit random coil conformations as shown by 13C
secondary chemical shifts of Cα and Cβ (see Supplementary
Figure 6A). Peptides without PTM or with S400-O-GlcNAc
have both a weak propensity of secondary structure along the
entire sequence as shown by neighbor-corrected Structural
Propensity (ncSP) calculation (Figure 4) (Tamiola and Mulder,
2012). In contrast, peptides with phosphorylation on S404
have a slight propensity to adopt helical conformation in the
C-terminal region (from S404 to L408) as highlighted by both
secondary structure propensity (SSP) based on 1Hα, 13Cα
and 13Cβ (Supplementary Figure 6B) (Marsh et al., 2006)
and ncSP scores based on 1HN, 15N, 1Hα, 13Cα and 13Cβ
(Figure 4). This structural propensity is more pronounced in
the presence of other PTMs, either phosphorylation of S396
(Tau[392-411]-2P) or double phosphorylation of S396/S400
(Tau[392-411]-3P) or glycosylation of S400 (Tau[392-411]-GP)
while the N-terminal region (from I392 to D402) have an even
more pronounced extended conformation upon multiple PTMs
(Figure 4). Conformational changes induced by pS404 and
enhanced by multiple PTMs are also evidenced by the extent of
perturbations of amide and Hα-Cα chemical shifts from R406
to N410 (see Supplementary Figures 5B, 7A,B). Together, these
data suggest that phosphorylation of S396, and phosphorylation
or O-GlcNAcylation of S400 have a remote effect on the
conformation of the region immediately downstream pS404
inducing a propensity to helical structure probably stabilized by
H-bond and/or salt bridges between pS404 and basic residues
within the C-terminus.
Effect of Phosphorylation and
O-GlcNAcylation of PHF-1 Epitope on
the Formation of Tau Fibrillar Aggregates
The effect of PTMs within the PHF-1 epitope was then
investigated at the functional level in Tau self-assembly into
fibrillar aggregates. Without external inducer, neither TauS262A-
P(GSK3), TauPHF1-P nor TauPHF1-PP were able to form
fibrils as monitored by Thioflavin T (ThT) fluorescence during
several days at 37◦C and negative-staining transmission electron
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FIGURE 5 | Aggregation of TauPHF1 series induced by heparin. (A,B) Kinetics of TauPHF1 aggregation probed by ThT fluorescence emission plotted as
mean ± standard deviation. (C,D) TEM images showing the fibril morphology of TauPHF1 isoforms with 20,000× (upper panels) and 85,000× (lower panels)
magnification. The scale bars of the upper panels correspond to 2 µm and for the lower panels to 500 nm. Isoforms that are non-phosphorylated by GSK3β (Tau,
Tau-G, and Tau-P) and phosphorylated by GSK3β (Tau-P(GSK3), Tau-G/P(GSK3), and Tau-PP) are depicted in (C) and (D), respectively. (E) Elongation rate
constants calculated from curves fitted with a one-phase association model. The color coding is the same for all panels as indicated in (C) and (D) for the different
TauPHF1 isoforms.
microscopy (TEM). Hence, we first stimulated aggregation of the
diverse phosphorylated/O-GlcNAcylated Tau isoforms by using
heparin and tracking aggregation kinetics by ThT fluorescence
combined with TEM imaging at the end-point of aggregation to
probe fibril morphology and extent. We have previously shown
that heparin as a polyanionic cofactor mainly interacts with
lysine residues in Tau protein with higher avidity for MTBR
and flanking regions (Sibille et al., 2006; Kamah et al., 2014).
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Hence, multiple mutations of Ser/Thr into Ala residues did not
significantly affect heparin binding to TauPHF1 mutant which
forms fibrillar aggregates with kinetics similar to TauS262A
(Figure 5A,D, see Supplementary Figures 8A, 9A). We have
observed the formation of filaments for the various PTM
isoforms of TauPHF1 with morphology similar to PHFs as
detected by TEM (Figure 5D). However, it has been described
that heparin-induced fibrils of Tau are polymorphic and
morphologically distinct from those extracted from AD brain
(Fichou et al., 2018d; Zhang et al., 2019). As the molecular
structure of fibrils from Tau PTM isoforms may be different from
bona fide PHFs, we hereafter referred them to PHF-like fibrils.
Formation of filaments of TauPHF1 proteins was modulated
by the different PTMs. Notably, O-GlcNAcylation reduces
the elongation rate of TauPHF1 as previously shown (Yuzwa
et al., 2012). However, ThT signal of TauPHF1-G was increased
significantly at end-point of aggregation reactions although about
3 times lower than TauPHF1 (Figures 5A,B, see Supplementary
Figures 8A–C). TEM examination and measurement of
variations in the amount of soluble TauPHF1-G before and
at the end of aggregation indicate a high content of fibrils
together with a significant decrease of soluble protein suggesting
that O-GlcNAcylation does not prevent fibrillar assembly of
Tau (Figures 5B,D, see Supplementary Figures 8D,E). While
both CDK2 and sequential CDK2/GSK3β phosphorylation
strongly decrease TauS262A aggregation, aggregation of
TauPHF1 was modulated by the sole phosphorylation of
PHF-1 epitope in different way depending on kinase involved:
CDK2 phosphorylation decreases the rate of fibril formation
while GSK3β phosphorylation stimulates aggregation of all
proteins - Tau-P(GSK3), Tau-PP and Tau-G/P(GSK3) - as
shown by comparing the elongation rate constants derived
from aggregation kinetics with values of Tau proteins before
GSK3β phosphorylation - Tau, Tau-P and Tau-G, respectively
(Figure 5C). GSK3β phosphorylation after CDK2 priming or
without priming leads to similar patterns of phosphorylation in
TauPHF1 mutant primarily defined by a high level of PHF1-3P
(Figure 2A) and same aggregation kinetics of PHF-like fibril
formation (Figures 5A–C). In contrast, even though GSK3β
phosphorylation stimulates aggregation of Tau-G, it does not
restore the aggregation rate at the level of non-modified Tau
but rather parallel the aggregation kinetics of Tau-P. Together,
these data indicate that the PHF1-3P isoform plays an active role
in Tau aggregation and O-GlcNAcylation although decreasing
the elongation rate and modulating the extent of PHF1-3P
isoform interferes only weakly with the fibrillar assembly of
phosphorylated Tau.
TauS262A mutant phosphorylated by CDK2 or sequentially
by CDK2 and GSK3β (TauS262A-P or TauS262A-PP), both
providing high levels of phosphorylation, only marginally forms
fibrillar aggregates using heparin as external inducer as compared
to the non-phosphorylated isoform (see Supplementary
Figures 9A,B). Phosphorylation, either high level or site-specific,
probably competes with heparin binding making it impossible to
use and meaningless. Along this line, other PTM of Tau could also
modulate fibril formation by interfering with inducer binding
complicating data interpretation. To circumvent issues related
to potential reduction of heparin binding upon phosphorylation
and/or O-GlcNAcylation, we have then investigated aggregation
induced by seeds formed with TauS262A in the presence
of heparin. ThT fluorescence was only weakly increased in
aggregation reactions of soluble, monomeric Tau proteins at
25 µM in the presence of a 10-fold dilution of seeds rendering
difficult the interpretation and comparison of kinetics parameters
(see Supplementary Figures 10A,B). However, observation of
PHF-like fibrils by TEM clearly indicate an increase of the fibril
content and length in the presence of monomeric Tau proteins
bearing diverse PTMs as compared to seeds alone. A high content
of isolated and clusters of long PHF-like fibrils were observed for
both TauS262A and TauS262A-G proteins while only individual
short-length fibrils were detected for seeds alone (Figure 6). In
contrast, phosphorylated forms of TauS262A and TauS262A-G
prevents the formation of clusters of fibrils and promote rather
individual PHF-like filaments longer than those observed in
seeds alone. In TauPHF1 isoforms, phosphorylation by GSK3β
of either Tau, Tau-P or Tau-G promotes the formation of large
fibrillar clusters constituted of long PHF-like filaments (see
Supplementary Figure 11A).
DISCUSSION
We have investigated phosphorylation of Tau by GSK3β
with and without priming by CDK2, with and without
prior O-GlcNAcylation by OGT to probe modulation of
GSK3β-mediated phosphorylation pattern and its role on Tau
self-assembly into PHF-like filaments. The phosphorylation
pattern provided by GSK3β in TauS262A is highly regulated by
CDK2 priming. While only the triple phosphorylated state of
PHF-1 epitope or PHF1-3P (pS396/pS400/pS404) was observed
without priming as previously shown (Leroy et al., 2010),
prior CDK2 priming provides additional phosphorylation in
the PRD. CDK2 phosphorylates the AT180 phospho-epitope
(pT231/pS235) and AT8 epitope in its double phosphorylated
state or AT8-2P (pS202/pT205). Other phosphorylations were
also detected in the PRD (pT153, pT175, pT181, pT212) with
pT212 and pS202 that serves as priming sites for phosphorylation
by GSK3β of S208 and pS198, respectively, leading to a triple
phosphorylated state of AT8 or AT8-3P (pS202/pT205/pS208)
(Despres et al., 2017). Together, most of phosphorylation sites
were found within the C-terminal half of TauS262A protein with
an overall high phosphorylation level of 17± 1 phosphate per Tau
when sequentially combining CDK2 and GSK3 phosphorylation,
in agreement with physiological Tau expressed in Sf9 eukaryotic
cells (Drepper et al., 2020).
On the other hand, O-GlcNAcylation by OGT is solely
localized within the C-terminus of Tau at S400, S412 and S413
residues. With or without CDK2 priming, OGT glycosylation
only regulates phosphorylation of PHF-1 epitope primarily
through S400 O-GlcNAcylation embedded in that epitope (at a
level of ca. 60%), acting by both decreasing phosphorylation on
S404 and disrupting sequential phosphorylation of S400/S396
by GSK3β as previously described in peptides (Smet-Nocca
et al., 2011) while priming by CDK2 on S404 is not affected.
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FIGURE 6 | Transmission electron micrographs with negative staining of fibrillar aggregation of TauS262A protein series induced by Tau seeds prepared with
TauS262A and heparin (ratio 4:1) for 7 days at 37◦C, diluted 10-fold in 25 µM monomeric Tau (gray), Tau-P (red), Tau-PP (black), Tau-G (green), Tau-G/P (pink) and
Tau-G/PP (purple) showing three different magnification: 20,000× (A), 50,000× (B) and 85,000× (C). The scale bar of 2 µm applies to panels (A), 500 nm to panels
(B,C).
FIGURE 7 | Phosphorylation pattern of GSK3β at the PHF-1 epitope without CDK2 priming and its regulation by O-GlcNAc. (A,B) overlaid 1H-15N-HSQC NMR
spectra of TauPHF1-G/P(GSK3β) (orange), TauPHF1-P (red), and TauPHF1-PP (black) showing the resonance multiplicity of pS404 depending on the modification
state of S400. (C) Graphical representation of levels of S400 modifications (S400, pS400, or gS400) depending on the phosphorylation state of S404 in
TauPHF1-G/P(GSK3β) (orange bars) as compared to TauPHF1-P(GSK3β) (blue bars). Phosphorylation levels of S400 are depicted by filled areas, O-GlcNAcylation
levels by shaded areas and no PTM by dotted areas. (D) Schematic representation of phospho-/O-GlcNAc-isoforms of the PHF-1 epitope with their respective
distribution in TauPHF1-G, TauPHF1-P(GSK3β) and TauPHF1-G/P(GSK3β).
Formation of PHF1-3P by GSK3β without priming by CDK2
was decreased upon O-GlcNAcylation from about 65% to 14%
(Figures 3A, 7C). Phosphorylation and O-GlcNAcylation of
respective S404 and S400 sites are not exclusive as they co-exist in
an isoform representing 21% of all isoforms. However, the gS400
glycosylation, differentially distributed into pS404 and S404
isoforms, is prevalent in the non-phosphorylated S404 isoform
(see Supplementary Figure 12). This is in agreement with what
we have previously shown with phosphorylation of Tau-G by
the kinase activity of a rat brain extract (Bourré et al., 2018).
Furthermore, O-GlcNAcylation not only reduces the formation
of PHF1-3P epitope but also decreases S404 phosphorylation in
the S400 non-O-GlcNAc fraction pointing to regulatory role of
other O-GlcNAc sites at S412 and S413 in modulation of PHF-1
phosphorylation.
From a conformational point of view, our NMR data indicate
that amide resonances of pS404 or S404 are sensors of the
PTM state of S400, and conversely (Figures 2C,D, 3C,D, and
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Supplementary Figures 1C,D) underpinning a spatial proximity
of both sites and potential conformational crosstalk. The study
of local conformational changes induced by PTM of the PHF-
1 epitope was performed in small peptides (Table 2 and
Supplementary Figures 5A,B) ranging from residue 392 to
411 using NMR chemical shifts. Chemical shift index (Wishart
et al., 1992, 1995) and secondary chemical shift (Wishart
et al., 1991; Wishart, 2011) analyses based on 13Cα and
13Cβ indicate a random coil conformation for Tau[392-411]
peptides independently of their PTM status (see Supplementary
Figure 6A). Chemical shift analyses of Tau[392-411] peptides
with SSP and ncSP indicate an extended conformation for the
N-terminal region (from residue 392 to 402) while the peptide
C-terminus displays conformational changes according to PTM
involved. An extended conformation of a di-phosphorylated
peptide, pS396/pS404, was revealed by an X-ray structure
of the PHF-1 epitope in complex with a monoclonal Tau
antibody emphasizing side chain interactions between Y394
and pS396 stabilized by specific interactions with an antigen
binding site (Chukwu et al., 2018). In 1H-15N HSQC spectra
of pS396-containing Tau isoforms and peptides, a large shift
was observed for K395 resonance upon S396 phosphorylation
(see Supplementary Figures 4A,C, 5A, 7B) while perturbations
of chemical shifts of surrounding residues such as Y394 are
weaker. This suggests that adjacent K395 and pS396 residues
engage in a salt bridge as also shown in MD simulations of
model peptides of similar sequence surrounding a phospho-
site (Rani and Mallajosyula, 2017). It has been proposed that
an intramolecular salt bridge between lysine or arginine side
chain and phosphate locks the peptide in a Poly-Proline II
(PPII) conformation. In RT231PP sequence of Tau, a salt bridge
interaction between R230 and pT231 was suggested to compete
with an intermolecular salt bridge with tubulin (Schwalbe et al.,
2015). Similarly, phosphorylation of S396 could lock both K395
and S396 in a salt bridge preventing interactions of these residues
with other partners.
On the other hand, chemical shift analyses with SSP and
ncSP highlight a helical propensity in the C-terminus of
peptides containing phosphorylation at S404 (Figure 4). In
contrast, none of individual phosphorylation on S396 or S400 or
O-GlcNAcylation of S400 induce similar conformational changes
(see Supplementary Figure 6B). The S404 phosphorylation-
induced conformational change is in agreement with what
was previously observed for phosphorylation of AT180 epitope
where phosphorylation of T231/S235 induces a N-cap stabilizing
a α-helix in the C-terminal region of phosphorylation sites
(from S237 to A246) (Bielska and Zondlo, 2006; Sibille
et al., 2011). Interestingly, the helical conformation tendency
induced by pS404 is exacerbated when other PTMs are present
on either S396 and/or S400. Surprisingly, O-GlcNAcylation
(Tau[392-411]-GP) induces the same effect on the C-terminus
conformation as single phosphorylation of S396 (Tau[392-411]-
2P) or double phosphorylation of S396/S400 (Tau[392-411]-
3P) (Figure 4). It was shown in Tau peptides from PRD
that phosphorylation induces the formation of a PPII helix
while O-GlcNAcylation have an opposite role by destabilizing
it (Brister et al., 2014). In a study performed in model
α-helical peptides, both phosphorylation and O-GlcNAcylation
localized at the N-terminus of an α-helix were shown to
stabilize it with a greater effect for phosphorylation over
O-GlcNAcylation, and both destabilize it when localized within
the helix sequence with a greater effect for O-GlcNAcylation
(Elbaum and Zondlo, 2014). Here, in the PHF-1 epitope,
phosphorylation of S396 and S400 as well as O-GlcNAcylation
of S400 are located in an extended N-terminal region with
respect to those of helical propensity and remotely stabilize
a conformational change induced by phosphorylation of S404.
Such conformational changes may have critical implications in
interactions of Tau with microtubules or other binding partners,
in regulating Tau function of tubulin polymerization or self-
assembly into fibrils.
The role of PHF-1 phosphorylation and O-GlcNAcylation
in fibrillar aggregation was then investigated in vitro in
the presence of heparin or seeds of Tau2N4R to induce
aggregation. High level or site-specific phosphorylation are
likely to compete with Tau binding to heparin due to charge
repulsion, as illustrated by all phosphorylated isoforms of
TauS262A and TauS262A-G (see Supplementary Figures 9A–
C). Phosphorylation sites encompassed in the PRD are prone
to interfere with heparin binding due to a high proportion of
positively charged residues, especially lysine residues, in this
region involved in heparin interactions while the C-terminal
domain contains a lower concentration of binding sites (Sibille
et al., 2006; Kamah et al., 2014; Despres et al., 2019). Hence,
phosphorylation of PHF-1 epitope is less likely to interfere
with heparin binding than multiple phosphorylation within the
PRD. Reducing phosphorylation sites in TauPHF1 mutant leads
to appreciable aggregation rates of phosphorylated isoforms
as measured by ThT fluorescence and sizable amounts of
PHF-like fibrils observed by TEM. In this aggregation set-
up in which heparin stimulates the formation of filaments,
phosphorylation by CDK2 (Tau-P) as well as O-GlcNAcylation
by OGT (Tau-G) both reduce fibrillar aggregation rates with
a greater effect for O-GlcNAcylation, which also affects the
initial phase of fibrillization related to nucleation processes
(Figure 5, see Supplementary Figure 8). Nevertheless, significant
increase of ThT fluorescence and decrease of soluble protein
content at aggregation end-point as well as large amounts
of PHF-like filaments shown by TEM (Figure 5D, see
Supplementary Figure 8) indicate that O-GlcNAcylation does
not prevent fibrillar assembly of Tau but only reduces the
elongation rate.
In contrast, phosphorylation by GSK3β accelerates
aggregation rates of Tau, Tau-P or Tau-G isoforms by 1. 5-,
3.3- and 7.1-fold, respectively (Figure 5C). Each of the respective
phospho-isoforms resulting from GSK3β phosphorylation
contains PHF1-3P epitope at a relative level of 65%, 75% and
14% (Figures 2A, 3A, 7C). Even though Tau-G/P(GSK3β) still
contains a significant amount of non-phosphorylated gS400
isoform (48%) that was shown to strongly inhibit the aggregation
rate, GSK3β phosphorylation significantly stimulates fibrillar
assembly even with a low amount of PHF1-3P. Together these
data indicate that the PHF1-3P isoform is a potent stimulant of
Tau fibrillization. Along this line, it was previously shown that
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the C-terminus displays an inhibitory role in Tau assembly and
that inhibition can be partly reversed by pseudo-phosphorylation
at the PHF-1 epitope (S396E/S404E) or truncation of the
C-terminus (Abraha et al., 2000). Moreover, we have shown
in peptides that a combination of S400 O-GlcNAcylation and
S404 phosphorylation induces similar conformational changes
in the region downstream S404 as PHF1-3P. Therefore, in
Tau-G/P(GSK3β), the significant amount of gS400/pS404
isoform (21%) could also contribute to a large extent to
acceleration of Tau fibrillar aggregation thereby counteracting
the O-GlcNAc-mediated inhibition. This would suggest that a
combination of phosphorylation and O-GlcNAcylation could
be deleterious in the same way than PHF-1 phosphorylation in
fibrillar assembly.
We have shown here that seeds of Tau2N4R formed with
heparin are able to induce fibrillar aggregation of monomeric
TauS262A isoforms bearing various PTMs into PHF-like
filaments as detected by TEM (Figure 6). Despite the large
amount of fibrillar material, increase of ThT signals was by
far weaker as compared to those of aggregation reactions of
TauPHF1 series induced by heparin, and the variations of ThT
emission signal is too weak to be interpreted unambiguously.
It must be noticed, however, that ThT signals at the initial
time is high as compared to aggregation reactions induced
by heparin and higher than those of seeds alone, and there
is no lag phase as well. This argues that Tau seeds promote
aggregation of monomeric Tau regardless of the PTM status
by reducing the nucleation rate as previously described (Meyer
et al., 2014; Dinkel et al., 2015) even in the absence of external
cofactors. In our setup, a 10-fold dilution of seeds made of
Tau2N4R pre-incubated with heparin leads to a final heparin
dilution with monomeric Tau (equivalent to 0.25 µM heparin
for 25 µM monomeric Tau considering the initial heparin
concentration used to prepare seeds) beyond a concentration
in which heparin is able to efficiently promote aggregation (see
Supplementary Figure 10C). It is likely that most of heparin
used to prepare seeds is incorporated into fibrils and a very low
amount is expected to be available to induce aggregation of fresh
monomers. Fichou et al. have shown that Tau fibrils induced by
heparin dissociate upon treatment with heparinase concluding
that heparin is an essential cofactor of Tau aggregation and
a cofactor is required to sustain fibril seeding (Fichou et al.,
2018c, 2019). However, it appears in our study that Tau seeds
without additional heparin are able to stimulate fibril formation
but the content of fibrils is limited by the amount of seeds and
rapidly reaches a plateau. TEM imaging of aggregation reactions
of monomeric Tau and Tau-G shows the presence of individual
filaments together with large clusters of fibrils while seeds alone
are made of individual fibrils of shorter length (Figure 6).
These observations indicate that Tau seeds allow Tau and
Tau-G monomers to aggregate and O-GlcNAcylation does not
intrinsically inhibit the fibrillization process. Phosphorylation of
both Tau and Tau-G, on the other hand, induce the formation
of individual fibrils to a lesser extent with greater length
than seeds and no fibrillar clusters were observed indicating a
distinct mechanism of fibrillization as compared to the non-
phosphorylated isoforms. This suggests that at least part of
heparin within Tau seeds is still accessible as shown in Fichou
et al. (2018c), and reduces interactions of phosphorylated Tau
species with seeds. In contrast, seeding of TauPHF1 aggregation
also shows that GSK3β phosphorylation significantly stimulates
the formation of PHF-like filaments of Tau, Tau-P and Tau-
G isoforms as shown by a greater extent of long fibrillar
species and clusters, and the significant reduction of soluble
Tau monomers at aggregation end-point (see Supplementary
Figures 11A,C,D).
A reciprocal regulation of Tau phosphorylation and
O-GlcNAcylation has been shown in various cellular models
of tauopathies or in vivo in transgenic mice. In most cases,
decreasing protein O-GlcNAcylation through OGT knock-down
or by mimicking impaired glucose metabolism and uptake as
in AD brain leads to increased site-specific phosphorylation
of Tau (Liu et al., 2004, 2009). Conversely, Thiamet-G, a
potent OGA inhibitor, increases protein O-GlcNAcylation
in the brain of TG mice, reduces Tau phosphorylation and
alleviates Tau pathology (Yuzwa et al., 2008; Hastings et al.,
2017). However, Thiamet-G injection was also shown to trigger
GSK3β activation leading to an increased site-specific Tau
phosphorylation (Yu et al., 2012). The proposed mechanism
was that increased O-GlcNAcylation leads to inhibition of
AKT that negatively regulates GSK3β by phosphorylation
of serine 9. Here, we have shown that O-GlcNAcylation
modulates GSK3β phosphorylation of PHF-1 epitope as
previously observed in peptides (Smet-Nocca et al., 2011), but
does not modify CDK2 priming nor remote phosphorylation
in the proline-rich domain excluding an extended effect
of O-GlcNAcylation on phosphorylation distributed along
the entire Tau protein. Furthermore, O-GlcNAcylation does
not antagonize the conformational changes induced by
phosphorylation of S404 nor the increased fibrillization
properties of GSK3β-phosphorylated Tau. Our data sustain
the hypothesis that regulation of Tau phosphorylation and
aggregation as well as neurodegeneration through O-GlcNAc
modulation (e.g., with OGA inhibitors) is likely an indirect
process involving the O-GlcNAc-mediated regulation of
enzymes implicated in phosphorylation dynamics (Lubas
and Hanover, 2000; Dias et al., 2012; Shi et al., 2012; Wang
et al., 2012; Xie et al., 2016) or other actors in Tau pathology
(Smet et al., 2004b; Landrieu et al., 2006; Lippens et al., 2007;
Borghgraef et al., 2013).
CONCLUSION
In this study, we have shown that GSK3β exacerbates
fibrillar aggregation of Tau protein in vitro and significantly
counteracts inhibition of fibrillization mediated by O-GlcNAc
posttranslational modifications although O-GlcNAcylation
severely reduces the PHF1-3P isoform. Conversely, priming
by CDK2 increases GSK3β phosphorylation in both Tau
and O-GlcNAcylated Tau isoforms by providing a number of
phosphorylation sites in the proline-rich domain which otherwise
is not targeted by GSK3β activity. A conformational study of
the impact of PTMs in the C-terminal region around the PHF-1
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epitope shows that phosphorylation of S404 triggers a dynamic
conformational change in the region immediately downstream
S404 site that is enhanced by other phosphorylations of the PHF-
1 epitope or S400 O-GlcNAcylation. These data suggest that
multiple phosphorylations or combination of phosphorylation
and O-GlcNAcylation within the PHF-1 epitope have the same
conformational effect while increasing the formation of PHF-
like filaments.
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